

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Beswick <i>et al.</i>	Confirmation No.:	4905
Serial No.:	10/518,778	Filing Date:	December 17, 2004
Patent No.:	7,199,239 B2	Issue Date:	April 3, 2007
Title:	CHEMICAL COMPOUNDS		

**Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR §1.322**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge any fees or to credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

2157e

**Jennifer L. Fox**  
**Attorney for Patentee**  
**Registration No. 52,218**

Date: 20 Sept 07

Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: (919) 483-6334  
Facsimile: (919) 483-7988

**ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON September 20, 2007.**

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,199,239 B2

Page 1 of 1

APPLICATION NO. : 10/518,778

ISSUE DATE : April 3, 2007

INVENTOR(S) : Beswick *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page:

A citation in Item (56) should read as follows:

(56)	References Cited		
	FOREIGN PATENT DOCUMENTS		
	FR	2273518	1/1976
	WO	WO 00/23407	4/2000
	-- EP	1067109	1/2001 --
	WO	WO 02/28821	4/2002

In the Claims:

Claim 10 in Column 88 (Line 18) should read as follows:

-- alkyl, halogen, or CN is attached to the R<sup>6</sup> substituent at the --

Claim 11 in Column 89 (Lines 18-19) should read as follows:

-- (4-([Butyl(4'-chloro-2-methyl-1,1'-biphenyl-3-yl)amino]methyl)-2-methylphenoxy)acetic acid; --

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

GLAXOSMITHKLINE  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.